Literature DB >> 8671821

Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.

S J Davies1, J Bryan, L Phillips, G I Russell.   

Abstract

BACKGROUND: Peritoneal infection and poor ultrafiltration continue to be the major causes of treatment failure in CAPD. The combined effects of peritonitis and the continuous exposure to dialysis fluid remain the most likely candidates affecting the peritoneum in the long term. The purpose of this study was to observe the effects of peritonitis and dialysis on longitudinal peritoneal function.
METHODS: The peritoneal equilibration test (PET) was utilized to quantify longitudinal changes in low-molecular-weight solute transfer (D/P(creat)) and ultrafiltration (UF) in 233 patients treated with CAPD. Of these, 166 represented an unselected cohort (Group 1) studied prospectively from commencing treatment for up to 54 months, and 67 were selected patients (Group 2) with PET data available at commencement of the study, having been on dialysis for a minimum of 18 months. PETs were performed either 6-monthly or following peritonitis episodes.
RESULTS: Data on the short-term effect of peritonitis kinetics were pooled for groups 1 and 2. Single, isolated episodes (n = 86) had no significant effect on D/P(creat) or UF, whereas recurrences or clusters of infection (n = 70) caused increases in D/P(creat) and reductions in UF, the significance of which increased with the number of episodes. There were significant correlations between both changes in D/P(creat) and UF with the cumulative dialysate leukocyte count, regardless of infecting organism, suggesting that intensity of peritoneal inflammation is also important. Those organisms associated with greater change in peritoneal kinetics, e.g. S. aureus, Pseudomonas, also had the highest neutrophil counts. The longitudinal changes in peritoneal kinetics were analysed for patients in group 1 only. There was a highly significant increase in D/P(creat) after 6 months treatment; this increased further with time on treatment, reaching further significance at 42 and 48 months. There was an associated reduction in UF. In view of the short-term effects of peritonitis on kinetics group 1 was further subdivided into patients who were either peritonitis free or only experienced isolated infections, group 1a, and those that had multiple infection episodes, group 1b. Treatment drop-out, due to death or technical failure occurred at double the rate in group 1b, who also had significantly higher D/P(creat) and lower UF at 1, 6, 12, 18 and 24 months of treatment. Group 1a subsequently caught up, however, indicating that peritonitis is not the only factor influencing long-term changes in peritoneal kinetics.
CONCLUSIONS: These data suggest that solute transfer increases and UF declines with time on peritoneal dialysis. This process is exacerbated and accelerated by peritonitis, and appears to be proportional to the degree of associated inflammation and number of infections in close proximity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671821

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  55 in total

1.  The Mutual Relationship Between Peritonitis and Peritoneal Transport.

Authors:  Sadie van Esch; Anouk T N van Diepen; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

2.  Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.

Authors:  Cengiz Candan; Pınar Turhan; Lale Sever; Mahmut Civilibal; Nur Canpolat; Salim Caliskan; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-01-29       Impact factor: 3.714

3.  The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function.

Authors:  M José Fernández-Reyes; M Auxiliadora Bajo; Gloria Del Peso; Marta Ossorio; Raquel Díaz; Beatriz Carretero; Rafael Selgas
Journal:  Perit Dial Int       Date:  2012-04-02       Impact factor: 1.756

4.  The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.

Authors:  Yu-Pei Fan; Ching-Chih Hsia; Kuang-Wen Tseng; Chih-Kai Liao; Tz-Win Fu; Tsui-Ling Ko; Mei-Miao Chiu; Yang-Hsin Shih; Pei-Yu Huang; Yi-Chia Chiang; Chih-Ching Yang; Yu-Show Fu
Journal:  Stem Cells Transl Med       Date:  2015-12-30       Impact factor: 6.940

5.  Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model.

Authors:  Zhenyuan Li; Hao Yan; Jiangzi Yuan; Liou Cao; Aiwu Lin; Huili Dai; Zhaohui Ni; Jiaqi Qian; Wei Fang
Journal:  Clin Exp Nephrol       Date:  2017-07-14       Impact factor: 2.801

6.  Chronic infusion of sterile peritoneal dialysis solution abrogates enhanced peritoneal gene expression responses to chronic peritoneal catheter presence.

Authors:  El Rasheid Zakaria; Paul J Matheson; Ryan T Hurt; Richard N Garrison
Journal:  Adv Perit Dial       Date:  2008

7.  Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis.

Authors:  Gareth W Roberts; Duncan Baird; Kathleen Gallagher; Rhiannon E Jones; Christopher J Pepper; John D Williams; Nicholas Topley
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

Review 8.  Peritoneal dialysis associated infections: An update on diagnosis and management.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2012-08-06

Review 9.  Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions.

Authors:  Ahad Qayyum; Elizabeth Ley Oei; Klara Paudel; Stanley L Fan
Journal:  World J Nephrol       Date:  2015-02-06

10.  Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis.

Authors:  Paulina M Kowalewska; Peter J Margetts; Alison E Fox-Robichaud
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.